INTRODUCTION {#s1}
============

Patients receiving hemodialysis tend to lack essential nutrients because of the dietary restriction and loss caused by dialysis therapy, resulting in the development of various clinical symptoms owing to the deficiencies. Carnitine is an essential nutrient that transports fatty acid into mitochondria and is stored mainly in muscles. Recent findings have revealed that patients receiving hemodialysis have a lower serum carnitine level and lower carnitine pool in their muscles, indicating carnitine deficiency, and that L-carnitine supplementation improves their skeletal muscle discomfort and fatigue \[[@r1]\].

Patients receiving hemodialysis also manifest gastrointestinal symptoms such as constipation \[[@r2]\]. The restriction of water intake and the loss of body water balance may induce constipation, and it might elevate blood urea nitrogen (BUN) level in hemodialysis patients. Because dietary carnitine deficiency in infancy is considered to cause smooth muscle dysmotility of the gastrointestinal tract similarly to that in their skeletal muscles in the extremities, carnitine deficiency in hemodialysis patients may be one cause of gastrointestinal discomfort and dysfunctions \[[@r3]\]. However, the effects of carnitine supplementation on hemodialysis patients with gastrointestinal disorders remain to be evaluated \[[@r4]\]. Recently, it has been sensationally reported that CKD and/or uremia alters the human gut microbiota \[[@r5], [@r6]\].

Therefore, we investigated the changes in the clinical symptoms, metabolic parameters, and intestinal microbiota of chronic hemodialysis patients who received L-carnitine supplementation.

SUBJECTS AND METHODS {#s2}
====================

We performed a multicenter nonrandomized single-arm prospective clinical trial of outpatients receiving hemodialysis at Keio University Hospital and Murai Clinic, Japan. We enrolled 15 patients who had been receiving hemodialysis, and written informed consents was obtained from all the patients. L-carnitine tablets (900 mg) were administered for 3 months, and clinical and biochemical analyses were performed before and after the treatment. The conditions of hemodialysis (mode, dialysis hours per week, membrane surface area and material, and blood flow) in each patient were not changed throughout the study period. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Review Board of Keio University (No. 2011-366, March 26, 2012). This study was also registered as a clinical study in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR: No. UMIN000007677).

Body weight increase and pre- and postdialysis session blood pressures were calculated as the mean of 6 dialysis sessions. The frequency of passing stool per a week was counted before and after L-carnitine treatment. Myasthenia was evaluated using the following scale: 1, sometimes happen after dialysis and disappears within 30 min; 2, always happens after dialysis and continue for 2 hours; 3, always happens during dialysis and continue for 4 hours or longer. Blood samples were drawn from the arterial site of the arteriovenous fistula at the start or end of each dialysis session after a 2-day interval at 0 and 3 months after enrolment. Blood cell counts and the levels of BUN, serum creatinine, total protein, albumin, hemoglobin, and brain natriuretic peptide were measured by standard laboratory techniques using an auto-analyzer. Total, free, and acyl carnitine measurements were entrusted to Bio-Medical Laboratories, Inc. (Tokyo, Japan), and measured by enzyme cycling methods. Insulin resistance was assessed using plasma immunoreactive insulin (IRI) and homeostasis model assessment for insulin resistance (HOMA-R), with HOMA-R = fasting glucose (mg/dl) × fasting IRI (mU/ml)/405 \[[@r7]\].

Extraction and analysis of fecal microbiota were performed as reported previously \[[@r8]\]. Briefly, fecal samples were suspended in sterile distilled water by vigorous shaking, and the supernatant was transferred to a 0.5 ml tube containing glass beads (0.1 mm diameter), before being spun at 5,000 rpm for 3 min in a mini-bead beater (BioSpec Products, Bartlesville, OK, USA). DNA was extracted from the bead-treated suspension using phenol-chloroform extraction and isopropanol precipitation.

To enable terminal restriction fragment length polymorphism (T-RFLP) analysis, PCR was performed using the total fecal DNA and 25 µM primers for labelled 516f (TGCCAGCAGCCGCGGTA) and l510r (GGTTACCTTGTTACGACTT). The PCR conditions were as follows: 95°C for 15 min; 30 cycles of 95°C for 30 sec, 50°C for 30 sec, and 72°C for 2 min; and a final extension step of 72°C for 10 min. The resultant amplicons were digested with 2 U BslI (New England Biolabs Japan, Tokyo, Japan) for 1 h and then fractionated using an automated sequence analyzer (ABI PRISM 3130xl Genetic Analyzer, Applied Biosystems, Foster City, CA, USA). The lengths and peak areas of the fragments were determined using GeneMapper software (Applied Biosystems, Foster City, CA, USA). The relative abundance of operational taxonomic units (OTUs) was calculated by dividing the peak area of each OTU by the sum of all the peak areas. This T-RFLP analysis revealed the relative abundances of the phyla of Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria, the order of Lactobacillales, and the genus of *Clostridium* subcluster 4.

The relative abundances of *Clostridium* subcluster 4 of bacteria in the fecal samples were evaluated using quantitative PCR, which was performed using SYBR Green (Takara Bio, Kusatsu, Shiga, Japan) and an Mx3000P real-time PCR system (Agilent Technologies Japan Ltd., Tokyo, Japan), as reported previously \[[@r9]\]. The amplification procedure consisted of 1 cycle of 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. All experiments were performed in duplicate, and melting curve analysis was performed after the amplification stage to exclude nontarget reactions. The frequencies of specific bacteria were calculated as ratios of the total number of bacteria. The total number of bacteria was assessed using universal primers for total bacteria \[[@r10], [@r11]\].

Data were expressed as mean ± standard error values. The significance of differences between 2 groups was examined using Student t-test or the Wilcoxon signed-rank test. P-values of \< 0.05 were considered to indicate a statistically significant difference.

RESULTS {#s3}
=======

Fifteen Japanese patients receiving hemodialysis completed the study. They consisted of 6 men and 9 women aged 72 ± 10 years. They had a dialysis history of 12 ± 7.9 years, and 4 of the patients had diabetes mellitus. The patients' characteristics at baseline and after 3 months of treatment are shown in [Table 1](#tbl_001){ref-type="table"}Table 1.Clinical profile of the patients before and after oral L-carnitine supplementation0 month3 monthsPredialysisPostdialysisPredialysisPostdialysisBW increase(kg)1.9 (0.1)1.8 (0.1)%DW(%)3.8 (0.3)4.0 (0.2)Systolic blood pressure(mmHg)121 (6)124 (5)Diastolic blood pressure(mmHg)67 (3)69 (3)Serum total carnitine(μmol/l)40.9 (2.6)172.3 (19.0)\*35.0 (17.0)Serum free carnitine(μmol/l)25.2 (1.7)115.5 (12.4)20.6 (3.3)Serum acyl carnitine(μmol/l)15.7 (1.1)56.8 (7.1)\*14.5 (3.6)Acyl/free carnitine0.63 (0.03)0.50 (0.03)0.68 (0.09)Hemoglobin(g/dl)10.9 (0.3)10.9 (0.3)Serum albumin(g/dl)3.7 (0.1)3.6 (0.43)Serum total cholesterol(mg/dl)180 (11)173 (9)Blood urea nitrogen(mg/dl)61.5 (4.3)18.1 (1.3)57.1 (3.3)\*15.9 (1.5)Serum creatinine(mg/dl)10.5 (1.8)3.9 (1.2)10.3 (1.8)4.0 (1.1)Plasma potassium(mEq/l)4.8 (0.2)5.1 (0.2)Serum phosphate(mg/dl)5.2 (0.3)5.7 (0.3)HOMA-IR7.2 (1.6)6.2 (1.4)Plasma BNP(pg/ml)551 (132)457 (120)Data are expressed as means (SEM). The comparisons between the carnitine values were carried out using the predialysis values. \*p\<0.05 compared with 0 month.BW: body weight; DW: dry weight for dialysis session; HOMA-IR: homeostasis model assessment for insulin resistance; BNP: brain natriuretic peptide.. Seven patients used laxative agents at study registration. The serum total carnitine level was increased significantly by supplementation with carnitine for 3 months (from 40.9 ± 2.6 μmol/l to 172.3 ± 19.0 μmol/l, p\<0.05). This finding shows that the patients adhered to the treatment of carnitine supplementation. Consistent with previous reports, the myasthenia score was decreased significantly by the administration of L-carnitine (from 1.3 ± 0.3 to 0.8 ± 0.2, p\<0.05). These findings indicated that the oral L-carnitine supplementation effectively remedied the deficiency of the systemic carnitine pool and the clinical symptoms caused by the deficiency in our patients.

Next, the effects of carnitine supplementation on the gastrointestinal tract were investigated. The frequency of passing stool per week was examined before and after supplementation. The frequency of passing stool tended to increase with treatment for 3 months (from 4.2 ± 0.5 times/week to 4.8 ± 0.5 times/week; not significantly different). Seven of the 15 subjects took laxatives before the administration of carnitine, whereas 5 of the 15 subjects took laxatives after the administration of carnitine. Regarding the resolution of constipation, the predialysis BUN level decreased significantly after 3 months of supplementation (from 61.5 ± 4.3 mg/dl to 57.1 ± 3.3 mg/dl, p\<0.05). Dry weight and the increase in body weight between the patients' hemodialysis sessions (from 1.9 ± 0.1 kg to 1.8 ± 0.1 kg) were not significantly changed after supplementation, indicating that their nutritional status did not markedly change for 3 months. Serum creatinine levels were not significantly changed during the study, indicating that the effects of hemodialysis were also not changed. Therefore, the decrease in the BUN level after supplementation might have been attributable to the changes in their gastrointestinal conditions.

Moreover, because the intestinal microbiota can be modulated by intestinal conditions, analyses of the intestinal microbiota were conducted. A phyla-level analysis of the microbiota showed that the composition of the individual microbiota was not different between before and after supplementation ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.The relative abundance of intestinal bacteria in the hemodialysis patients before and after oral L-carnitine supplementation for 3 months.Fifteen patients who were receiving hemodialysis and had low serum carnitine levels were administered L-carnitine (900 mg) for 3 months, and stool samples were collected before and after treatment. Bacterial 16S rDNA was extracted from the fecal samples, amplified by PCR, and subjected to terminal restriction fragment length polymorphism (T-RFLP) analysis. (A) The relative abundances of each speculated bacterial phyla to total bacteria are shown as means ± SEM. (B) The relative abundances of Lactobacillales and *Clostridium* subcluster 4 are shown as means ± SEM. Black bar, before treatment; white bar, after treatment.). This finding was consistent with a previous report indicating that the composition of the intestinal microbiota is preserved individually \[[@r12]\]. An order- and genus-level analysis, however, revealed a significant decrease in the relative abundances of the genus *Clostridium* subcluster 4 caused by the supplementation treatment (from 7.7 ± 1.9% to 4.7 ± 1.3%, p\<0.05) ([Fig. 1](#fig_001){ref-type="fig"}). Because the major component of *Clostridium* subcluster 4 in the human intestinal microbiota is *Clostridium leptum*, the relative abundance of *Clostridium leptum* was investigated by the genus-specific quantitative PCR method. The relative abundance of *Clostridium* subcluster 4 as shown by the T-RFLP method was significantly correlated with the relative amount of *Clostridium leptum* measured by the quantitative PCR method ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2.The relative abundance of intestinal *Clostridium* subcluster 4 and *Clostridium leptum* in the hemodialysis patients before and after oral L-carnitine supplementation for 3 months.The relative abundances of *Clostridium* subcluster 4 measured by the T-RFLP method are shown on the horizontal axis, and the relative abundances of *Clostridium leptum* measured by the quantitative PCR method are shown on the vertical axis. Closed circles, before treatment; open circles, after treatment., r=0.91; p\<0.05). Therefore, supplementation of L-carnitine to the patients receiving hemodialysis was found to alter their intestinal microbiota significantly.

DISCUSSION {#s4}
==========

Recent findings have shown that the composition of the intestinal microbiota is skewed in patients with chronic kidney disease and end-stage renal disease and that an intervention targeting the microbiota might prevent the progression of renal dysfunction \[[@r6], [@r13]\]. As the Lactobacillaceae and Prevotellaceae families were shown to decrease in CKD patients, the supplementation with probiotics including *Lactobacillus acidophilus* was performed in CKD patients \[[@r14]\]. This treatment reportedly decreased the BUN level in the CKD patients. In patients treated with hemodialysis, supplementation with *Lactobacillus* was found to decrease their serum nitrogen metabolite levels and improve their muscle volume and appetite \[[@r15]\]. These reports suggested that the modulation of dysbiosis found in patients with end-stage renal disease would be beneficial for renal function and nitrogen control.

Instead of modulation of the intestinal microbiota by microorganisms, the medication for constipation was shown to also alter the intestinal environment with changes in the microbiota to protect against the progression of CKD \[[@r16]\]. Uremic toxins such as indoles are produced by the intestinal microbiota, and these toxins worsen renal function and the prognosis of end-stage renal disease \[[@r17]\]. We showed that oral supplementation with L-carnitine improved gastrointestinal disorders and nitrogen management in patients receiving hemodialysis. Although the precise mechanism of the improvement induced by L-carnitine is unclear, the improvement in gastrointestinal dysmotility might contribute to the beneficial effect. Further investigation of the underlying mechanism is essential for carnitine therapy.

The limitations of the study are the small number of enrolled patients, the lack of a placebo control, and the insufficient accuracy of the microbiota analysis. Although the number of the patients was limited, the consistency of the intestinal microbiota between before and after treatment indicated that the alternation of specific bacterial species would have important implications. The effect of hemodialysis on the intestinal microbiota should have been excluded by a placebo group. Alternation of the intestinal microbiota, however, was not observed in participants treated with plasmapheresis for hyperlipidemia (data not shown). Thus, the effects of the hemodialysis procedure on the intestinal microbiota might be excluded. In order to investigate the alteration of the intestinal microbiota caused by L-carnitine in detail, a meta-16S rDNA analysis, which was recently developed, should be conducted to determine the species-level changes in the intestinal microbiota. Although the analytical method used in this study did not possess the power to detect species-level changes, the observed decrease in *Clostridium* subcluster 4 was verified by two independent methods. Further studies are needed to clarify which species was changed by the therapy.

CONCLUSION {#s5}
==========

In summary, the oral supplementation of L-carnitine to the patients receiving hemodialysis improved not only their muscle discomfort but also their gastrointestinal disorders and microbiota. The effect of supplementation with L-carnitine on the prognosis of hemodialysis patients should be further investigated.
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